Healthcare Professionals2019-06-06T16:40:13+00:00

What makes Eversense® different?

The real-time insights provided by CGM can help many insulin-dependent patients improve glycemic control,4 but the burdens of traditional CGM limit adherence and resulting efficacy. The Eversense Long-Term CGM System is uniquely engineered to overcome many of these burdens and unleash the potential of CGM. 

Fully implantable, long-lasting sensor: Once inserted, patients have the flexibility to remove the transmitter without replacing the sensor.

Improved glycemic control: The Eversense CGM System uses threshold and predictive alerts to detect 95% of hypoglycemic episodes (70 mg/dL) and 99% of hyperglycemic episodes (180 mg/dL) within a 15-minute window.3

Alerts patients can see, feel, and hear: In the event of an impending low or high glucose, the Eversense Long-Term CGM System can provide visual, audible, and on-body vibe alerts.

A broader patient fit: Every patient is different, and some patients are less able to deal with the complexity and burden of traditional CGM. By reducing complexity and burden, Eversense may be a better fit with patients’ lifestyles and needs.

The Eversense Long-Term CGM System, a new alternative to traditional CGM.

The Eversense Sensor

  • Placed subcutaneously in the upper arm during an in-office procedure that takes just a few minutes
  • Excellent accuracy for up to 3 months of wear
  • Accuracy not impacted by exercise or compression

The Eversense Smart Transmitter

  • Calculates and transmits glucose data every 5 minutes via Bluetooth® LE
  • Provides on-body vibe alerts that can be felt while sleeping

  • Can be removed and reattached without wasting a sensor

The Eversense Mobile App

  • Displays real-time glucose data discreetly on the user’s mobile device or Apple Watch®

  • Eliminates the need to carry a separate receiver, further reducing complexity and visibility of diabetes disease state

  • Provides threshold, predictive, and rate of change alerts

  • Compatible with Android™ and iOS smartphones and tablets

How Eversense can enhance care and clinical practices.

Diabetes is a demanding condition for patients as well as providers, and Eversense is designed to help reduce these demands, while advancing care cadence and clinical practice goals.

  • Ensures patients return for scheduled three-month sensor insertion and follow-up

  • Fewer sensors and supplies required

  • Reimbursement opportunities for insertion, activation, and replacement

  • Fewer sensor errors, variability, and time spent educating and troubleshooting

Ordering Information

How to apply for remibursement

To order or learn more about how Eversense is changing diabetes management call 844-SENSE4U (844-736-7348) today.

MKT-001204 01
  1. Kropff, J., Choudhary, P., Neupane, S., Barnard, K., Bain, S. C., Kapitza, C., … & DeVries, J. H. (2017). Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial. Diabetes Care, 40(1), 63-68. (PRECISE I).
  2. Christiansen MP, Kla LJ, Brazg R, et al. A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206.
  3. Data on file. Senseonics 2018
  4. Beck RW, MD, Hirsch IB, Lael L, Tamborlane WV, et al. Eect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes. Diabetes Care. 2009 August; 32(8): 1378–1383.
  5. Summary of Safety and Eectiveness Data (SSED) Medical Device Databases –
  6. Lind M, Polonsky, W, Hirsch, I, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Injections – The GOLD Randomized Clinical Trial. [published online January 24, 2017]. JAMA.
  7. Beck R, Riddlesworth, T, Ruedy, K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 1 Diabetes Using Injections for Insulin Delivery: The DIAMOND Randomized Clinical Trial. [published online January, 24, 2017]. JAMA.